1
|
Van Maele L, Carnoy C, Cayet D, Songhet P, Dumoutier L, Ferrero I, Janot L, Erard F, Bertout J, Leger H, Sebbane F, Benecke A, Renauld JC, Hardt WD, Ryffel B, Sirard JC. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol 2010; 185:1177-85. [PMID: 20566828 PMCID: PMC3060348 DOI: 10.4049/jimmunol.1000115] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In adaptive immunity, Th17 lymphocytes produce the IL-17 and IL-22 cytokines that stimulate mucosal antimicrobial defenses and tissue repair. In this study, we observed that the TLR5 agonist flagellin induced swift and transient transcription of genes encoding IL-17 and IL-22 in lymphoid, gut, and lung tissues. This innate response also temporarily enhanced the expression of genes associated with the antimicrobial Th17 signature. The source of the Th17-related cytokines was identified as novel populations of CD3(neg)CD127(+) immune cells among which CD4-expressing cells resembling lymphoid tissue inducer cells. We also demonstrated that dendritic cells are essential for expression of Th17-related cytokines and so for stimulation of innate cells. These data define that TLR-induced activation of CD3(neg)CD127(+) cells and production of Th17-related cytokines may be crucial for the early defenses against pathogen invasion of host tissues.
Collapse
Affiliation(s)
- Laurye Van Maele
- CIL, Centre d'infection et d'immunité de Lille
INSERM : U1019Institut Pasteur de LilleLille,FR
- UMR 8204
CNRS : UMR 8204Université Lille NordLille,FR
| | - Christophe Carnoy
- CIL, Centre d'infection et d'immunité de Lille
INSERM : U1019Institut Pasteur de LilleLille,FR
- UMR 8204
CNRS : UMR 8204Université Lille NordLille,FR
| | - Delphine Cayet
- CIL, Centre d'infection et d'immunité de Lille
INSERM : U1019Institut Pasteur de LilleLille,FR
- UMR 8204
CNRS : UMR 8204Université Lille NordLille,FR
| | - Pascal Songhet
- ETH Zürich, Eldgenössische Technische Hochschule Zürich
ETH ZurichHauptgebäude Rämistrasse 101 8092 Zürich Schweiz Telefon: +41 44 632 11 11 Telefax: +41 44 632 10 10,CH
| | - Laure Dumoutier
- Ludwig Institute for Cancer Research
Ludwig Institute for Cancer ResearchBrussels Branch, Brussels,BE
- Université Catholique de Louvain
Université Catholique de LouvainBE
| | - Isabel Ferrero
- Ludwig Institute for Cancer Research
Ludwig Institute for Cancer ResearchUniversité de LausanneEpalinges,CH
| | - Laure Janot
- IEM, Immunologie et embryologie moléculaires
CNRS : UMR6218Université d'Orléans3B rue de la Ferollerie 45071 ORLEANS CEDEX 2,FR
| | - François Erard
- IEM, Immunologie et embryologie moléculaires
CNRS : UMR6218Université d'Orléans3B rue de la Ferollerie 45071 ORLEANS CEDEX 2,FR
| | - Julie Bertout
- MCM, Médecine cellulaire et moléculaire
CNRS : IFR142INSERMInstitut Pasteur de LilleUniversité des Sciences et Technologies de Lille - Lille IUniversité du Droit et de la Santé - Lille II1 rue du Professeur Calmette 59019 LILLE CEDEX,FR
| | - Hélène Leger
- IHES, Institut des Hautes Etudes Scientifiques
IHES35 route de Chartres 91440 Bures sur Yvette,FR
- USTL, Institut de Recherche Interdisciplinaire
CNRS : USR3078Université Lille NordLille,FR
| | - Florent Sebbane
- CIL, Centre d'infection et d'immunité de Lille
INSERM : U1019Institut Pasteur de LilleLille,FR
- UMR 8204
CNRS : UMR 8204Université Lille NordLille,FR
| | - Arndt Benecke
- IHES, Institut des Hautes Etudes Scientifiques
IHES35 route de Chartres 91440 Bures sur Yvette,FR
| | | | - Wolf-Dietrich Hardt
- ETH Zürich, Eldgenössische Technische Hochschule Zürich
ETH ZurichHauptgebäude Rämistrasse 101 8092 Zürich Schweiz Telefon: +41 44 632 11 11 Telefax: +41 44 632 10 10,CH
| | - Bernhard Ryffel
- IEM, Immunologie et embryologie moléculaires
CNRS : UMR6218Université d'Orléans3B rue de la Ferollerie 45071 ORLEANS CEDEX 2,FR
- USTL, Institut de Recherche Interdisciplinaire
CNRS : USR3078Université Lille NordLille,FR
| | - Jean-Claude Sirard
- CIL, Centre d'infection et d'immunité de Lille
INSERM : U1019Institut Pasteur de LilleLille,FR
- UMR 8204
CNRS : UMR 8204Université Lille NordLille,FR
| |
Collapse
|
2
|
Kim DH, Yoo KH, Yim YS, Choi J, Lee SH, Jung HL, Sung KW, Yang SE, Oh WI, Yang YS, Kim SH, Choi SY, Koo HH. Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice. J Korean Med Sci 2006; 21:1000-4. [PMID: 17179676 PMCID: PMC2721918 DOI: 10.3346/jkms.2006.21.6.1000] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Transplantation of marrow-derived mesenchymal stem cells (MSCs), expanded by culture in addition to whole bone marrow, has been shown to enhance engraftment of human hematopoietic stem cells (HSCs). Our hypothesis was that there might be an optimum ratio range that could enhance engraftment. We examined the percent donor chimerism according to the ratio of HSCs to MSCs in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. We tested a series of ratios of co-transplanted CD34(+) -selected bone marrow cells, and marrow-derived MSCs into sublethally irradiated NOD/SCID mice. In all experiments, 1x10(5) bone marrow derived human CD34(+) cells were administered to each mouse and human MSCs from different donors were infused concomitantly. We repeated the procedure three times and evaluated engraftment with flow cytometry four weeks after each transplantation. Serial ratios of HSCs to MSCs were 1:0, 1:1, 1:2 and 1:4, in the first experiment, 1:0, 1:1, 1:2, 1:4 and 1:8 in the second and 1:0, 1:1, 1:4, 1:8 and 1:16 in the third. Cotransplantation of HSCs and MSCs enhanced engraftment as the dose of MSCs increased. Our results suggest that the optimal ratio of HSCs and MSCs for cotransplantation might be in the range of 1:8-1:16; whereas, an excessive dose of MSCs might decrease engraftment efficiency.
Collapse
Affiliation(s)
- Dong Hyun Kim
- School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Keon Hee Yoo
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Young Sook Yim
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Jaewon Choi
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Soo Hyun Lee
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Hye Lim Jung
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Ki Woong Sung
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Sung-Eun Yang
- Department of Research and Development for Cellular Therapy, Medipost Biomedical Research Institute, Seoul, Korea
| | - Won Il Oh
- Department of Research and Development for Cellular Therapy, Medipost Biomedical Research Institute, Seoul, Korea
| | - Yoon-Sun Yang
- Department of Research and Development for Cellular Therapy, Medipost Biomedical Research Institute, Seoul, Korea
| | | | - Sang-Yun Choi
- School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
| | - Hong Hoe Koo
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
3
|
Abstract
Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) has been reported to specifically kill malignant cells but to be relatively nontoxic to normal cells. One of disadvantages to previous in vivo protocols was the need for large quantities of TRAIL recombinant protein to suppress tumor growth. To evaluate the antitumor activity and therapeutic value of the TRAIL gene, we constructed adenoviral vectors expressing the human TRAIL gene (Ad.hTRAIL) and transferred them into malignant glioma cells in vitro and tumors in vivo, as an alternative to recombinant soluble TRAIL protein. The results show that TRAIL-sensitive glioma cells infected Ad.hTRAIL undergo apoptosis through the production and expression of TRAIL protein. The in vitro transfer elicited apoptosis, as demonstrated by the quantification of viable or apoptotic cells and by the analysis of cleavage of poly (ADP-ribose) polymerase. Furthermore, in vivo administration of Ad.hTRAIL at the site of tumor implantation suppressed the outgrowth of human glioma xenografts in SCID mice. These results further define Ad.hTRAIL as an anti-tumor therapeutic and demonstrate its potential use as an alternative approach to treatment for malignant glioma.
Collapse
Affiliation(s)
- Ki-Uk Kim
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Su-Yeong Seo
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Ki-Young Heo
- Department of Pathology, Pusan National University College of Medicine, Busan, Korea
| | - Young-Hyun Yoo
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Hye-Jin Kim
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Hyeong-Sik Lee
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Sun-Seob Choi
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Tae-Ho Hwang
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| | - Hye-Jeong Lee
- Brain Tumor Research, Dong-A University College of Medicine, Busan, Korea
| |
Collapse
|